FCNCA (First Citizens BancShares Inc) Stock Analysis - News

First Citizens BancShares Inc (FCNCA) is a publicly traded Financial Services sector company. As of May 20, 2026, FCNCA trades at $1,972.49 with a market cap of $22.51B and a P/E ratio of 11.35. FCNCA moved +2.39% today. Year to date, FCNCA is -9.61%; over the trailing twelve months it is +2.84%. Its 52-week range spans $1,473.62 to $2,412.93. Analyst consensus is buy with an average price target of $2,200.00. Rallies surfaces FCNCA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What changed in FCNCA news today?

Silicon Valley Bank Adds Six Specialists to Life Science & Healthcare Team: Silicon Valley Bank added six specialists to its Life Science & Healthcare team in New York, San Francisco and Boston to bolster sector expertise. They fill senior management, private credit and startup banking roles to expand debt financing, professional networks and clinical insights for biotech and healthtech firms.

FCNCA Key Metrics

Key financial metrics for FCNCA
MetricValue
Price$1,972.49
Market Cap$22.51B
P/E Ratio11.35
EPS$173.61
Dividend Yield2.10%
52-Week High$2,412.93
52-Week Low$1,473.62
Volume39.36K
Avg Volume0
Revenue (TTM)$9.56B
Net Income$2.26B
Gross Margin0.00%

Latest FCNCA News

Recent FCNCA Insider Trades

  • HOLDING FRANK B JR sold 5.35K (~$10.26M) on May 12, 2026.
  • HOLDING FRANK B JR bought 5.94K (~$10.26M) on May 12, 2026.
  • HOLDING FRANK B JR bought 92 (~$142.60K) on Mar 19, 2026.

FCNCA Analyst Consensus

7 analysts cover FCNCA: 0 strong buy, 2 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $2,200.00.

Common questions about FCNCA

What changed in FCNCA news today?
Silicon Valley Bank Adds Six Specialists to Life Science & Healthcare Team: Silicon Valley Bank added six specialists to its Life Science & Healthcare team in New York, San Francisco and Boston to bolster sector expertise. They fill senior management, private credit and startup banking roles to expand debt financing, professional networks and clinical insights for biotech and healthtech firms.
Does Rallies summarize FCNCA news?
Yes. Rallies summarizes FCNCA news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is FCNCA research on Rallies investment advice?
No. Rallies provides research, data, and educational context for FCNCA. It does not provide personalized investment advice.
FCNCA

FCNCA